The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography

Nuclear Medicine Communications

Volumn 31, Issue 2, 2010, Pages 128-136

  Özkol, Volkan ^a   Alper, Eray ^a   Aydn, Nesrin ^a   Özkol, Hayriye Funda ^a   Topal, Naile Bolca ^a   Akpnar, Ali Tayyar ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

18F fluorodeoxyglucose; Correlative methods; Incidental; Oncology; Positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER DIAGNOSIS; COLON ADENOMA; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EARLY DIAGNOSIS; ENDOMETRIUM CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHEOCHROMOCYTOMA; PHYSIOLOGY; PRECANCER; PRIMARY TUMOR; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 75149145111     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328332b30e     Document Type: Article

References (30)

1. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of 18F-FDG PET in evaluation of cancer patients. Radiographics 2003; 23:315-340.
2. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-332.
3. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49:480-508.
4. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 2004; 24:1411-1431.
5. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007; 48 (Suppl 1):78S-88S.
6. Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med 2004; 45:1816-1821.
7. Ben-Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J Nucl Cardiol 2006; 13:791-800.
8. Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of Infection and Inflammation. Radiographics 2005; 25:1357-1368.
9. Bleeker-Rovers CP, Vos FJ, Mudde AH, Dofferhoff AS, Geus-Oei LF, Rijnders AJ, et al. A prospective multi-centre study of the value of 18F-FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 2007; 34:694-703.
10. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 2009; 39:36-51.
11. Strobel K, Stumpe KD. PET/CT in musculoskeletal infection. Semin Musculoskelet Radiol 2007; 11:353-364.
12. Hartmann A, Eid K, Dora C, Trentz O, von Schulthess GK, Stumpe KD. Diagnostic value of 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur J Nucl Med Mol Imaging 2007; 34:704-714.
13. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005; 25:191-207.
14. Castellsague X, Quintana MJ, Martinez MC, Nieto A, Sanchez MJ, Juan A, et al. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer 2004; 108:741-749.
15. Van Westreenen HL,Westerterp M, Jager PL, van Dullemen HM, Sloof GW, Comans EF, et al. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med 2005; 46:1321-1325.
16. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 2006; 14:239-247.
17. Agress H, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004; 230:417-422.
18. Ishimori T, Patel PV, Wahl RL. Detection of unexpected second primary lesions in patients with known or suspected malignancy with PET/CT. J Nucl Med 2005; 46:752-757.
19. Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, et al. The presentation of malignant tumors and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006; 33:541-552.
20. Tatlidil R, Jadavar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002; 224:783-787.
21. Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake. J Nucl Med 2005; 46:758-762.
22. Chen YK, Kao CH, Liao AC, Shen YY, Su CT. Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer Res 2003; 23:4357-4361.
23. Gozu HI, Bircan R, Krohn K, Müller S, Vural S, Gezen C, et al. Similar prevalence of somatic TSH receptor and Gsa mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey. Eur J End 2006; 155:535-545.
24. Erdogan G, Erdogan MF, Emral R, Bastemir M, Sav H, Haznedaroglu D, et al. Iodine status and goiter prevalence in Turkey before mandatory iodization. J Endocrinol Invest 2002; 25:224-228.
25. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22:2167-2171.
26. Yoshida Y, Kurokawa T, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Incremental benefits of 18F-FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004; 182:227-233.
27. Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre-and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004; 45:266-271.
28. Kim S-K, Kang KW, Roh JW, Sim JS, Lee ES, Park S-Y. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging 2005; 32:757-763.
29. Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F-18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004; 171:1806-1809.
30. Drieskens O, Oyen R, Van Hoppel H, Vankan Y, Flamen P, Mortelmans L. 18F-FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005; 32:1412-1417.